United Therapeutics (UTHR) Long-Term Deferred Tax (2009 - 2026)

United Therapeutics has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $335.4 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $335.4 million, down 26.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $335.4 million (down 26.54% YoY), and the FY2025 annual result was $357.7 million, down 21.97% from the prior year.
• Long-Term Deferred Tax came in at $335.4 million for Q1 2026 at United Therapeutics, down from $357.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $458.4 million in Q4 2024 to a low of $271.8 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $354.9 million (2025), against an average of $360.3 million.
• Across the five-year window, Long-Term Deferred Tax increased 25.12% in 2022 and slipped 26.54% in 2026, its largest moves.
• United Therapeutics' Long-Term Deferred Tax stood at $327.7 million in 2022, then increased by 20.48% to $394.8 million in 2023, then gained by 16.11% to $458.4 million in 2024, then dropped by 21.97% to $357.7 million in 2025, then decreased by 6.23% to $335.4 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $335.4 million (Q1 2026), $357.7 million (Q4 2025), and $354.9 million (Q3 2025), per Business Quant data.